简体
  • 简体中文
  • 繁体中文

热门资讯> 正文

Cipher Pharmaceuticals报告财年业绩

2026-03-13 05:13

  • Cipher Pharmaceuticals press release (CPHRF): FY Revenue of $50.5M.
  • Full year net income of $27.3 million, an increase of 137% over fiscal 2024
  • Full year adjusted EBITDA1 of $28.1 million, an increase of 79% over fiscal 2024
  • Generated $8.7 million in cash from operations during Q4 2025 and $29.7 million for the full year
  • Debt repayments of $35.0 million in fiscal 2025, with $7.5 million cash balance which exceeds outstanding long-term debt of $5.0 million at December 31, 2025
  • $5.4 million in share repurchases under Normal Course Issuer Bid during fiscal 2025

风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。